Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Access Pharmaceuticals, an emerging biopharmaceutical company, has received notification from the Japan Patent Office that a patent for MuGard and ProctiGard has been granted.
Subscribe to our email newsletter
The patent covers a wide range of liquid formulations for the prevention and treatment of mucosal diseases and disorders.
"Following our recent European licensing agreement with Norgine, the strengthening of our world-wide intellectual property position for MuGard and ProctiGard further supports our commercial efforts and enhances our ability to license both supportive cancer care products in Japan," said Jeffrey Davis, President and CEO of Access.
"It is with this in mind that we continue to pursue opportunities within the Japanese market as we believe in the benefit both MuGard and ProctiGard can offer patients when undergoing anticancer treatments."
MuGard Mucoadhesive Oral Wound Rinse is indicated for the management of oral mucositis/stomatitis (that may be caused by radiotherapy and/or chemotherapy) and all types of oral wounds (mouth sores and injuries), including aphthous ulcers/canker sores and traumatic ulcers, such as those caused by oral surgery or ill-fitting dentures or braces.
MuGard provides the oral mucosa with a thin protective hydrogel layer which has been demonstrated in several clinical studies of mucositis to benefit patients in terms of reduced pain and discomfort as well as a reduction in objective mucositis scores.